Nicotinic receptor compounds
Compounds and compositions for promoting smoking cessation or decreasing tobacco use or nicotine addiction are provided. The compounds are 2′-fluoro-3′-(substituted phenyl) deschloroepibatidine analogs. The compounds have been found to modulate neuronal nicotine acetylcholine receptors and are useful in methods for the treatment of conditions or disorders influenced by the modulation of neuronal nicotinic acetylcholine receptors.
1. A compound represented by formula (I)
wherein X is H and Y is —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 CF 3 ; or X is —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 CF 3 , and Y is H; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein X is H and Y is —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 CF 3 , or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein X is —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 CF 3 , and Y is H, or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein X is —SO 2 CH 3 and Y is H, or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein X is —SO 2 NH 2 and Y is H, or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein X is —SO 2 CF 3 and Y is H, or a pharmaceutically acceptable salt thereof.
7. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
8. A method of treating nicotine addiction, comprising administering an effective amount of a composition of claim 7 to a subject in need thereof.
9. A method for selectively modulating the function of a nicotinic acetylcholine receptor comprising administering to a subject in need thereof an effective amount of a composition of claim 7 .
10. The method of claim 9 , wherein the selective modulation comprises inactivation of the function of one or more nicotinic acetylcholine receptor subtype as an antagonist.
11. A method for treating a subject having a condition or disorder selected from smoking addiction, nicotine addiction, or pain, the method comprising administering to said subject having or susceptible to said condition or disorder an effective amount of a compound represented by formula (I)
wherein X is H and Y is —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 CF 3 ; or X is —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 CF 3 , and Y is H; or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , wherein X is H and Y is —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 CF 3 , or a pharmaceutically acceptable salt thereof.
13. The method of claim 11 , wherein X is —SO 2 CH 3 , —SO 2 NH 2 , or —SO 2 CF 3 , and Y is H, or a pharmaceutically acceptable salt thereof.
14. The method of claim 11 , wherein X is —SO 2 CH 3 and Y is H, or a pharmaceutically acceptable salt thereof.
15. The method of claim 11 , wherein X is —SO 2 NH 2 and Y is H, or a pharmaceutically acceptable salt thereof.
16. The method of claim 11 , wherein X is —SO 2 CF 3 and Y is H, or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 , wherein Y is —SO 2 CH 3 and X is H, or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1 , wherein Y is —SO 2 NH 2 and X is H, or a pharmaceutically acceptable salt thereof.
19. The compound of claim 1 , wherein Y is —SO 2 CF 3 and X is H, or a pharmaceutically acceptable salt thereof.
20. The method of claim 11 , wherein Y is —SO 2 CH 3 and X is H, or a pharmaceutically acceptable salt thereof.